← Leaderboards
Avery D. Posey
Philadelphia Va Medical Center
$0
Attributed
$0
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2018–25$1$1$1$0$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
VA$0 · 2
By mechanism
I01$0 · 1
IK2$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Philadelphia Va Medical Center
Same institution · by research overlap
Others in their field
Other Emerging Leaders on “Solid Neoplasm”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$24,099,336
- Crystal Mackall · Children'S Hosp Of Philadelphia$17,235,767
- Bronwen Shaw · Medical College Of Wisconsin$10,707,191
- John Freymann · Leidos Biomedical Research, Inc.$8,749,308
Research focus
Solid NeoplasmVeteransEngineeringResistanceTargeted TreatmentTumorCellular ImmunotherapyEngineered T CellsMetastatic Prostate CancerMalignant Neoplasm Of ProstateMucin 1 ProteinPatient PopulationProvengeTreatment EfficacyBoneAntigensCancer PatientCancer DiagnosisMetastatic Neoplasm To The BoneAntitumor ResponseCar T Cell TherapyImmunosuppressionChimeric Antigen Receptor T CellsProstatic Neoplasms
Grant awards (7)
Optimizing Cell Therapy to Counter Adaptive Resistance Mechanisms in Prostate Cancer$0
I01 · FY2025 · VA · contact PI
Optimizing Cell Therapy to Counter Adaptive Resistance Mechanisms in Prostate Cancer$0
I01 · FY2024 · VA · contact PI
Engineered T Cells Targeting Abnormal Glycans in Metastatic Prostate Cancer$0
IK2 · FY2022 · VA · contact PI
Engineered T Cells Targeting Abnormal Glycans in Metastatic Prostate Cancer$0
IK2 · FY2021 · VA · contact PI
Engineered T Cells Targeting Abnormal Glycans in Metastatic Prostate Cancer$0
IK2 · FY2020 · VA · contact PI
Engineered T Cells Targeting Abnormal Glycans in Metastatic Prostate Cancer$0
IK2 · FY2019 · VA · contact PI
Engineered T Cells Targeting Abnormal Glycans in Metastatic Prostate Cancer$0
IK2 · FY2018 · VA · contact PI